Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1608 Trials   78055 News 


«12...1011121314151617181920...903904»
  • ||||||||||  Prolia (denosumab) / Amgen
    The Role of Full Femur Imaging for Early Detection of Incomplete Atypical Femur Fractures (ENDOExpo: Poster Area) -  Apr 27, 2025 - Abstract #ENDO2025ENDO_783;    
    Title: The Role of Full Femur Imaging for Early Detection of Incomplete Atypical Femur Fractures Introduction: Atypical femur fractures (AFFs) are a rare but serious complication linked to prolonged use of bisphosphonates and denosumab...After seven years on alendronate, she sustained a complete right AFF requiring intramedullary nailing...Incorporating FFI into routine osteoporosis care is not routinely implemented and may highlight a gap in current practice. This case emphasizes the need for clear guidelines on screening for AFFs and the potential role of FFI in personalized imaging protocols to enhance patient care.
  • ||||||||||  Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Use of Romosozumab for Osteoporosis in ?-Thalassemia Major (ENDOExpo: Poster Area) -  Apr 27, 2025 - Abstract #ENDO2025ENDO_780;    
    There are currently no reports examining the efficacy of the anabolic Romosozumab in TM.We report the use of Romosozumab in 2 patients with TM and severe osteoporosis.A 65-year-old male with TM on deferoxamine chelation, also had small vessel vasculitis requiring high doses of corticosteroids...Despite 5 years of zoledronic acid (ZA) treatment, there was ongoing decline in BMD at both lumbar spine and hip and he sustained a new L3 fracture...He tolerated Romosozumab well and is currently undergoing consolidation treatment with ZA.A 58-year-old Jehovah's Witness male with TM, osteoporosis and multiple fractures had been treated with various osteoporosis therapies over 20 years, including bisphosphonates, strontium ranelate and denosumab...The observed BMD gains were significant despite previous prolonged exposure to anti-resorptive therapy, and thus represents a promising treatment option in patients with TM and osteoporosis. A clinical trial to confirm these benefits is required.
  • ||||||||||  Prolia (denosumab) / Amgen
    From Bone Density to Bone Death: Osteonecrosis of the Jaw in a Patient with Minimal Risk Factors (ENDOExpo: Poster Area) -  Apr 27, 2025 - Abstract #ENDO2025ENDO_779;    
    It emphasizes the importance of careful monitoring during BP therapy, and also raises the concern about treatment options for managing worsening OP in patients with BRONJ. Non-BP therapies, such as denosumab or teriparatide, could be considered to prevent further bone loss and fractures, but also carries the risk of ONJ, although data is limited.
  • ||||||||||  Prolia (denosumab) / Amgen
    Does Excluding Regions of Interest Affect Least Significant Change (LSC) Calculations in Trabecular Bone Score (TBS)? (ENDOExpo: Poster Area) -  Apr 27, 2025 - Abstract #ENDO2025ENDO_773;    
    Recent recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF) suggest that TBS may be beneficial for monitoring treatment with denosumab and anabolic agents...In clinical practice, there are instances where certain regions of interest should be excluded. In line with recent ESCEO recommendations regarding treatment monitoring and TBS, we believe it is essential for each center to assess the LSC for various vertebral combinations.
  • ||||||||||  Prolia (denosumab) / Amgen
    Primary Hyperparathyroidism in a Patient with Osteogenesis Imperfecta Type I and Osteoporosis (ENDOExpo: Poster Area) -  Apr 27, 2025 - Abstract #ENDO2025ENDO_755;    
    She was diagnosed with osteoporosis after menopause in her early 50s and was started on risedronate...Although some treatments for osteoporosis and OI overlap, we have limited, long-term data on denosumab use...Routine measurement of calcium should be done in patients with OI as these conditions can occur and the diagnosis and opportunity for treatment can be missed. Additional studies are needed to establish this concurrence.
  • ||||||||||  Prolia (denosumab) / Amgen
    A Case of Parathyroid Crisis with EKG Changes Mimicking ST Elevation Myocardial Infarct (ENDOExpo: Poster Area) -  Apr 27, 2025 - Abstract #ENDO2025ENDO_750;    
    One case presented with both ST changes and elevated troponin levels, as in our patient, likely due to demand ischemia. Our case presented a particularly challenging diagnostic dilemma with the cooccurrence of ST elevation, up-trending troponins and new wall motion abnormalities on TTE, which suggested acute MI, but ultimately no culprit lesion was identified on angiography.
  • ||||||||||  Prolia (denosumab) / Amgen
    The Largest Study (LATVPHPT) on Primary Hyperparathyroidism Conducted at Riga East University Hospital, Latvia: Part Two (ENDOExpo: Poster Area) -  Apr 27, 2025 - Abstract #ENDO2025ENDO_747;    
    17.5% (n=31) of patients received oral bisphosphonates, 4.0% (n=7) - intravenous bisphosphonates, 8.5% (n=15) - denosumab, 1.1% (n=2) - medication holidays...High rates of skeletal complications and malignancies in PHPT emphasize its clinical impact. Precise imaging, timely diagnosis, and appropriate treatment are essential for managing its complex manifestations.
  • ||||||||||  Prolia (denosumab) / Amgen
    Ectopic Parathyroid Hormone Secretion: An Unusual Cause of Severe Hypercalcemia (ENDOExpo: Poster Area) -  Apr 27, 2025 - Abstract #ENDO2025ENDO_745;    
    The patient was treated with IV fluids, zoledronic acid, calcitonin, cinacalcet, and subsequently denosumab for refractory hypercalcemia. A significantly elevated PTH, which is usually a feature of parathyroid carcinoma, could also be due to production from a non-parathyroid malignancy.
  • ||||||||||  Prolia (denosumab) / Amgen
    The Calcium Bandits: A Case of Combination Lanreotide and Denosumab Induced Hypocalcemia. (ENDOExpo: Poster Area) -  Apr 27, 2025 - Abstract #ENDO2025ENDO_735;    
    This suggests that lanreotide has long term effect on calcium homeostasis, likely due to intestinal calcium malabsorption contributing to secondary hyperparathyroidism. This study shows that lanreotide decreases serum calcium enough to trigger increased PTH secretion from parathyroid glands.Lanreotide should be considered a risk factor for hypocalcemia, particularly in patients receiving denosumab.
  • ||||||||||  Prolia (denosumab) / Amgen
    Two Cases of Denosumab-induced Hypocalcemia in patients with Bariatric surgery (ENDOExpo: Poster Area) -  Apr 27, 2025 - Abstract #ENDO2025ENDO_732;    
    While effective in its role, denosumab can also disrupt the body's calcium homeostasis, potentially leading to hypocalcemia, especially in patients with pre-existing conditions that affect calcium metabolism. These cases underscore the importance of careful patient selection when prescribing Denosumab, particularly in those with a history of gastric bypass surgery and highlighting the importance of monitoring of serum calcium levels.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Unmasking a Rare Risk: Osteonecrosis of the Jaw Following Pembrolizumab Therap (ENDOExpo: Poster Area) -  Apr 27, 2025 - Abstract #ENDO2025ENDO_713;    
    This rare case highlights a serious potential complication of pembrolizumab. An increased awareness and multi-disciplinary approach is essential for early detection and effective management.
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    Not a Stroke: A Case of Sight Threatening Thyroid Eye Disease With Delayed Diagnosis (ENDOExpo: Poster Area) -  Apr 27, 2025 - Abstract #ENDO2025ENDO_407;    
    Unfortunately, there can be barriers to accessing the antibody treatment. These can include a need for follow-up with a hard-to-find thyroid eye disease specialist registered with the company, lack of insurance coverage, treatment expense, and a lack of infusion center nurses trained to assess hearing.
  • ||||||||||  Repatha (evolocumab) / Amgen, Astellas
    Breaking the Triglyceride Barrier: A Case of Severe Hypertriglyceridemia Management (ENDOExpo: Poster Area) -  Apr 27, 2025 - Abstract #ENDO2025ENDO_331;    
    Pharmacologic therapy included continuation of rosuvastatin 40 mg, fenofibrate 160 mg, and ezetimibe 10 mg. Patient was also started on Icosapent ethyl 2 g twice daily and Levothyroxine (LTX) was increased from 125 mcg to 150 mcg due to an elevated TSH level of 10.4
  • ||||||||||  Evkeeza (evinacumab-dgnb) / Regeneron
    Evinacumab as an Effective Treatment Option for Refractory Hypertriglyceridemia (ENDOExpo: Poster Area) -  Apr 27, 2025 - Abstract #ENDO2025ENDO_327;    
    Evinacumab may be an effective alternative agent for the management of chronic hypertriglyceridemia based on the robust effects seen in our patient. Future research is needed to explore evinacumab's therapeutic targets beyond LDL-C to better modify risk factors for atherosclerosis, as well as CAV progression in heart transplant recipients.
  • ||||||||||  Praluent (alirocumab) / Sanofi, Regeneron, Leqvio (inclisiran) / Novartis, Repatha (evolocumab) / Amgen, Astellas
    A Case Series of Heterozygous Familial Hypercholesteremia With PCSK9 Inhibitor Failure (ENDOExpo: Poster Area) -  Apr 27, 2025 - Abstract #ENDO2025ENDO_322;    
    Ezetimibe 10mg daily was added and patient is awaiting approval for inclisiran.CASE 2: An 18-year-old woman with type 1 diabetes and celiac disease was seen in September 2012 for dyslipidemia...Pravastatin 40 mg was started but discontinued due to myalgias...Further research is needed to understand the underlying mechanisms and the likelihood of this occurring in other patients. These cases also highlight the need for ongoing vigilance in patients with high cholesterol and HeFH to ensure optimal cardiovascular protection.
  • ||||||||||  Prolia (denosumab) / Amgen
    A study Of Denosumab In Children With Glucocorticoid-Induced Osteoporosis (ENDOExpo: Poster Area) -  Apr 27, 2025 - Abstract #ENDO2025ENDO_298;    
    Conclusion Real-world evidence has shown that the incidence of children with glucocorticoid-induced osteoporosis, has reduced dramatically over time, concurrently with increased use of biological agents to treat rheumatological disease in children. In this study, treatment with denosumab showed no statistical difference in increase from baseline in lumbar spine BMD Z-score.
  • ||||||||||  Lumakras (sotorasib) / Amgen
    Journal:  Oncogenic KRAS addiction states differentially influence MTH1 expression and 8-oxodGTPase activity in lung adenocarcinoma. (Pubmed Central) -  Apr 26, 2025   
    Conversely, KRAS depletion or its inhibition by AMG-510 (sotorasib) decreased MTH1 in KRASG12C-addicted LUAD cells...Our studies suggest that despite loss of KRAS dependency, LUAD cells retain the requirement for high MTH1 8-oxodGTPase activity due to redox vulnerabilities associated with AKT signaling. Thus, MTH1 may serve as a novel orthogonal vulnerability in LUAD that has lost KRAS addiction.
  • ||||||||||  ivabradine / Generic mfg.
    Journal:  Ivabradine exposures reported to United States poison centers 2015-2023. (Pubmed Central) -  Apr 26, 2025   
    Adults with unintentional, asymptomatic exposures to ivabradine may be candidates for home monitoring. In ivabradine exposures refractory to medical management, clinicians should consider cardiac pacing or other supportive measures as a temporizing measure.
  • ||||||||||  Prolia (denosumab) / Amgen
    Application of N-terminal telopeptide of type I collagen in the evaluation of bone metastasis degree and efficacy. () -  Apr 23, 2025 - Abstract #ASCO2025ASCO_7193;    
    uCr-corrected uNTX excretion rates can effectively reflect the severity and treatment response of bone metastases and have the potential to serve as a convenient auxiliary tool for the clinical management of patients with bone metastases. Combining uNTX measurements with traditional imaging examinations can further improve the assessment system for bone metastasis status and treatment efficacy.
  • ||||||||||  Imlygic (talimogene laherparepvec) / Amgen, Yondelis (trabectedin) / PharmaMar, J&J, Opdivo (nivolumab) / Ono Pharma, BMS
    Phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin for advanced leiomyosarcoma and liposaroma (NCT03886311). () -  Apr 23, 2025 - Abstract #ASCO2025ASCO_7153;    
    P2
    Taken together, the results indicate that the combination regimen of Talimogene laherparepvec, Nivolumab, and Trabectedin may be more effective than Trabectedin alone (Median PFS 4.1 months) as treatment for previously treated patients with advanced leiomyosarcoma and liposarcoma with manageable toxicity. A randomized phase 2 clinical trial is warranted to confirm these promising results.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka, Fruzaqla (fruquintinib) / Takeda, Stivarga (regorafenib) / Bayer
    Real-world evidence of fruquintinib (Fruq) efficacy after regorafenib (Rego) and trifluridine () -  Apr 23, 2025 - Abstract #ASCO2025ASCO_7055;    
    The data suggest flexibility in treatment choices, with Fruquintinib showing improved OS when used earlier in the treatment sequence. These findings underscore the importance of exploring optimal sequencing strategies and evaluating Fruquintinib as a potential option before other approved agents in the refractory setting.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Keytruda (pembrolizumab) / Merck (MSD), Herceptin (trastuzumab) / Roche
    "How much does your medication cost?": Assessing patient attitudes towards the costs of oncology medication to society. () -  Apr 23, 2025 - Abstract #ASCO2025ASCO_7026;    
    This study provides an insight into Irish breast cancer patient attitudes towards societal oncology drug costs. These findings indicate that Irish breast cancer patients find the societal costs of many commonly prescribed oncology medications to be unacceptable and that many of these patients have a desire to be better informed of these costs.
  • ||||||||||  Imlygic (talimogene laherparepvec) / Amgen, Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS
    Systemic therapies for advanced melanoma after immunotherapy failure: Efficacy and safety insights. () -  Apr 23, 2025 - Abstract #ASCO2025ASCO_6639;    
    Heterogeneity of study designs, response rates, and toxicity profiles complicate direct comparisons. Given the high efficacy, TIL therapy and TVEC should be considered as second line treatment options.